sleep inducing News
-
Should I get a Memory Foam or a Memory Gel mattress?
Sleep is a very important and prominent aspect of living a healthy lifestyle – a big contributor to healthy living. No amount of fitness can really help you if your sleep isn’t proper and/or regular. Proper sleep is necessary for normal functioning and productivity, as, if your body isn’t properly and completely rested, you will face severe fatigue, an overall sense of ...
-
Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with a Complete ...
By Nyxoah SA
-
Nyxoah Provides General Corporate Update
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implanted first U.S. patient in the DREAM IDE pivotal study in December 2020; there are currently ...
By Nyxoah SA
-
BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia
SERENITY III will evaluate the efficacy and safety of BXCL501 for at-home use Top-line pivotal data expected in 1H 2023 Estimated 23 million annual agitation episodes in the home-setting would more than double current market opportunity for BXCL501 in the U.S. 1-4 BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop ...
-
Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™
OTTAWA, ON, Nov. 29, 2021 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced positive initial clinical data from its ongoing Phase 2 clinical trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for cancer pain. QIXLEEF™ is a botanical inhaled investigational ...
-
BioXcel Therapeutics Announces FDA Approval of IGALMI (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder1 IGALMI demonstrated onset of action as early as 20 minutes and high response rate with both 120 mcg and 180 mcg doses in pivotal studies1 Up to 25 million agitation episodes for these two patient populations in the U.S. annually2-3 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you